Clinical Trial Update: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating combination chemotherapy with bevacizumab in advanced neuroendocrine tumors has been terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoid Tumor
• Islet Cell Tumor
• Lung Cancer
• Neoplastic Syndrome
• Neuroendocrine Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-12-26